专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07763286B2 Composition comprising an extract of Tiarella polyphylla and tiarellic acid isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity 有权
标题翻译：组合物，其包含从其中分离的天竺葵提取物和由其分离的含有抗炎，抗过敏和抗哮喘活性的叶酸
公开(公告)号：US07763286B2
公开(公告)日：2010-07-27
申请号：US11989053
申请日：2006-07-18
申请人： Hyeong Kyu Lee , Sei Ryang Oh , Kyung Seop Ahn , Joong Ku Lee , Sang Ku Lee , Jung Hee Kim , Doo Young Kim , Gui Hua Quan , Ok Kyoung Kwon , Eun Ah Kim , Soon Ja Choi , Guang Hai Shen , Mi Jin Kim , Bo Young Park , Byung Sun Min , Gyoon Hee Han , Hea Young Park , Gun Cheol Kim , Joo Heon Kim , So Young Kim
发明人： Hyeong Kyu Lee , Sei Ryang Oh , Kyung Seop Ahn , Joong Ku Lee , Sang Ku Lee , Jung Hee Kim , Doo Young Kim , Gui Hua Quan , Ok Kyoung Kwon , Eun Ah Kim , Soon Ja Choi , Guang Hai Shen , Mi Jin Kim , Bo Young Park , Byung Sun Min , Gyoon Hee Han , Hea Young Park , Gun Cheol Kim , Joo Heon Kim , So Young Kim
IPC分类号： A61K36/00 , A61K47/00
CPC分类号： C07J53/00 , A23L33/105 , A61K36/185 , Y10S514/826
摘要： The present invention relates to a composition comprising an extract of Tiarella polyphylla, and tiarellic acid isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract of Tiarella polyphylla and the tiarellic acid isolated therefrom shows the inhibitory effect on the LTC4 release in vitro test and the suppressive effect on the IgE level and the cytokine (IL-4, IL-5 and IL-13) production, airway hyperresponsiveness, and leukocyte infiltration in OVA-induced asthmatic mice. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.
摘要翻译：本发明涉及一种组合物，其中含有天竺葵提取物和从其中分离得到的具有抗炎，抗过敏和抗哮喘活性的天竺葵酸。 Tiarella polyphylla的提取物和从其中分离的tiarellic酸显示对LTC4释放体外试验的抑制作用和对IgE水平和细胞因子（IL-4，IL-5和IL-13）产生，气道高反应性的抑制作用，和OVA诱导的哮喘小鼠白细胞浸润。因此，它可以用作用于治疗和预防炎性，过敏性和哮喘性疾病的治疗剂或功能性保健食品。

2. 发明申请

US20090148542A1 Composition comprising an extract of tiarella polyphylla and tiarellic acid isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity 有权
标题翻译：组合物，其包含从其中分离的天竺葵提取物和由其分离的天竺葵酸，其具有抗炎，抗过敏和抗哮喘活性
公开(公告)号：US20090148542A1
公开(公告)日：2009-06-11
申请号：US11989053
申请日：2006-07-18
申请人： Hyeong Kyu Lee , Sei Ryang Oh , Kyung Seop Ahn , Joong Ku Lee , Sang Ku Lee , Jung Hee Kim , Doo Young Kim , Gui Hua Quan , Ok Kyoung Kwon , Eun Ah Kim , Soon Ja Choi , Guang Hai Shen , Mi Jin Kim , Bo Young Park , Byung Sun Min , Gyoon Hee Han , Hea Young Park , Gun Cheol Kim , Joo Heon Kim , So Young Kim
发明人： Hyeong Kyu Lee , Sei Ryang Oh , Kyung Seop Ahn , Joong Ku Lee , Sang Ku Lee , Jung Hee Kim , Doo Young Kim , Gui Hua Quan , Ok Kyoung Kwon , Eun Ah Kim , Soon Ja Choi , Guang Hai Shen , Mi Jin Kim , Bo Young Park , Byung Sun Min , Gyoon Hee Han , Hea Young Park , Gun Cheol Kim , Joo Heon Kim , So Young Kim
IPC分类号： A61K36/00 , C07J53/00 , A61P29/00 , A61P37/08 , A61P11/06
CPC分类号： C07J53/00 , A23L33/105 , A61K36/185 , Y10S514/826
摘要： The present invention relates to a composition comprising an extract of Tiarella polyphylla, and tiarellic acid isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract of Tiarella polyphylla and the tiarellic acid isolated therefrom shows the inhibitory effect on the LTC4 release in vitro test and the suppressive effect on the IgE level and the cytokine (IL-4, IL-5 and IL-13) production, airway hyperresponsiveness, and leukocyte infiltration in OVA-induced asthmatic mice. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.
摘要翻译：本发明涉及一种组合物，其中含有天竺葵提取物和从其中分离得到的具有抗炎，抗过敏和抗哮喘活性的天竺葵酸。 Tiarella polyphylla的提取物和从其中分离的tiarellic酸显示对LTC4释放体外试验的抑制作用和对IgE水平和细胞因子（IL-4，IL-5和IL-13）产生，气道高反应性的抑制作用，和OVA诱导的哮喘小鼠白细胞浸润。因此，它可以用作用于治疗和预防炎性，过敏性和哮喘性疾病的治疗剂或功能性保健食品。

3. 发明申请

US20070066577A1 BENZOXAZOLE DERIVATIVE OR ANALOGUE THEREOF FOR INHIBITING 5-LIPOXYGENASE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 审中-公开
标题翻译：苯并噻唑衍生物或其类似物，用于抑制含有5-LIPOXYGENASE的药物组合物
公开(公告)号：US20070066577A1
公开(公告)日：2007-03-22
申请号：US11549280
申请日：2006-10-13
申请人： Hea Young Park Choo , Hyeong-Kyu Lee , Sei-Ryang Oh , Kyungseop Ahn , Gyoonhee Han , Joo Heon Kim
发明人： Hea Young Park Choo , Hyeong-Kyu Lee , Sei-Ryang Oh , Kyungseop Ahn , Gyoonhee Han , Joo Heon Kim
IPC分类号： A61K31/4745 , A61K31/655 , A61K31/428 , A61K31/423 , C07D498/02 , C07D491/02
CPC分类号： A61K31/423 , A61K31/428 , A61K31/4745 , C07D263/58 , C07D277/64 , C07D277/66 , C07D417/04 , C07D513/04
摘要： A novel benzoxazole derivative of formula (I) or a pharmaceutically acceptable salt thereof is effective for inhibiting 5-lipoxygenase which is useful for preventing or treating leukotriene-related diseases. The prevention also provides a pharmaceutical composition containing same and a method for preventing or treating leukotriene-related diseases.
摘要翻译：式（I）的新型苯并恶唑衍生物或其药学上可接受的盐可有效抑制用于预防或治疗白三烯相关疾病的5-脂氧合酶。该预防还提供含有其的药物组合物和预防或治疗白三烯相关疾病的方法。

4. 发明申请

US20140072664A1 DAPHNE GENKWA EXTRACTS, AND PHARMACEUTICAL COMPOSITION CONTAINING FRACTIONS OF THE EXTRACTS OR COMPOUNDS SEPARATED FROM THE EXTRACTS AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING ATOPIC DERMATITIS 有权
标题翻译： DAPHNE GENKWA提取物和含有提取物或化合物的化合物的药物组合物作为用于预防或治疗原发性成分的活性成分
公开(公告)号：US20140072664A1
公开(公告)日：2014-03-13
申请号：US14117737
申请日：2012-05-17
申请人： Jae Wha Kim , Kyung Seop Ahn , Ho Bum Kang , Sei Ryang Oh , Jae Jong Go , Joo Heon Kim , Jang Mi Sun , Jae Sung Song , Hyun Woo Oh , Da Jung Ji
发明人： Jae Wha Kim , Kyung Seop Ahn , Ho Bum Kang , Sei Ryang Oh , Jae Jong Go , Joo Heon Kim , Jang Mi Sun , Jae Sung Song , Hyun Woo Oh , Da Jung Ji
IPC分类号： C07D493/08 , A61K36/83
CPC分类号： C07D493/08 , A23L2/52 , A23L7/198 , A23L33/105 , A61K9/0019 , A61K9/0095 , A61K9/2018 , A61K9/4858 , A61K31/357 , A61K36/83 , A61K47/26 , A61K2236/00
摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of Daphne genkwa, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.
摘要翻译：本发明涉及用于预防或治疗特应症的药物组合物，其包含从其作为活性成分分离的化合物的Daphne genkwa的提取物，其分数。更准确地说，本发明的达芙妮genkwa的提取物，其分数或从其分离的基因苦参素或元华辛可以增加Th1免疫细胞中细胞因子的分泌并抑制特应性小鼠模型中的特应性，使得达芙妮genkwa的提取物，其分数或与本发明相同的化合物可以有效地用于预防或治疗特应性。

5. 发明授权

US09428520B2 Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis 有权
$Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis$
标题翻译：达芙妮genkwa提取物和含有从提取物中分离的提取物或化合物的部分的药物组合物作为预防或治疗特应性皮炎的活性成分
公开(公告)号：US09428520B2
公开(公告)日：2016-08-30
申请号：US14117737
申请日：2012-05-17
申请人： Jae Wha Kim , Kyung Seop Ahn , Ho Bum Kang , Sei Ryang Oh , Jae Jong Go , Joo Heon Kim , Jang Mi Sun , Jae Sung Song , Hyun Woo Oh , Da Jung Ji
发明人： Jae Wha Kim , Kyung Seop Ahn , Ho Bum Kang , Sei Ryang Oh , Jae Jong Go , Joo Heon Kim , Jang Mi Sun , Jae Sung Song , Hyun Woo Oh , Da Jung Ji
IPC分类号： A61K36/83 , A61K36/185 , C07D319/06 , C07D493/08 , A61K31/357 , A61K47/26 , A61K9/00 , A61K9/20 , A61K9/48 , A23L1/30 , A23L2/52 , A23L1/10
CPC分类号： C07D493/08 , A23L2/52 , A23L7/198 , A23L33/105 , A61K9/0019 , A61K9/0095 , A61K9/2018 , A61K9/4858 , A61K31/357 , A61K36/83 , A61K47/26 , A61K2236/00
摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of Daphne genkwa, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.
摘要翻译：本发明涉及用于预防或治疗特应症的药物组合物，其包含从其作为活性成分分离的化合物的Daphne genkwa的提取物，其分数。更准确地说，本发明的达芙妮genkwa的提取物，其分数或从其分离的基因苦参素或元华辛可以增加Th1免疫细胞中细胞因子的分泌并抑制特应性小鼠模型中的特应性，使得达芙妮genkwa的提取物，其分数或与本发明相同的化合物可以有效地用于预防或治疗特应性。

6. 发明申请

US20120315284A1 COMPOSITION FOR ENHANCING TRAIL SENSITIVITY COMPRISING INHIBITORS FOR EXPRESSION OR ACTIVITY OF TIP41 AS A TARGET GENE OF TRAIL SENSITIZER 有权
标题翻译：用于增强包含抑制剂的TRAIL敏感性的组合物，用于表达或活化TIP41作为TRAIL SENSITIZER的目标基因
公开(公告)号：US20120315284A1
公开(公告)日：2012-12-13
申请号：US13579256
申请日：2011-04-01
申请人： Nam-Soon Kim , In-Sung Song , Cheol-Hee Kim , Ga Hee Ha , Hyun-Taek Kim , So-Young Jeong , Jeong-Min Kim , Joo Heon Kim , Jin-Man Kim , Soo Young Jun
发明人： Nam-Soon Kim , In-Sung Song , Cheol-Hee Kim , Ga Hee Ha , Hyun-Taek Kim , So-Young Jeong , Jeong-Min Kim , Joo Heon Kim , Jin-Man Kim , Soo Young Jun
IPC分类号： A61K39/395 , G01N33/53 , G01N33/566 , A61K38/00 , A61K38/17 , A61K31/7088 , A61P35/00 , A61P29/00 , A61P37/00 , A61P17/00 , A61P37/08 , A61P1/04 , A61P1/00 , A61P19/02 , A61P21/00 , A61P31/14 , A61P25/00 , A61P3/10 , A61P7/06 , C12Q1/68
CPC分类号： A61K38/16 , A61K31/7105
摘要： The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway. Taken together, the present invention provide the strong evidence that the pharmaceutical composition, including inhibitors for TIP41 expression or activity can be used for cancer prevention and treatment as well as an anti-cancer adjuvant. Taken together, the pharmaceutical composition comprising inhibitors for expression or activity of TIP41 protein may be used for prevention and treatment of cancer or as an anti-cancer adjuvant.
摘要翻译：本发明涉及包含用于预防和治疗癌症的TIP41蛋白表达或活性抑制剂的药物组合物。当显示对TRAIL的抗性的肝癌细胞系用TIP41 siRNA和TRAIL处理时，在癌细胞中诱导细胞凋亡。在具有抗TRAIL的肺癌和结肠癌的情况下也发现了相同的效果。此外，在注射Huh7肝癌细胞的肿瘤异种移植物中证实了TIP41 siRNA和TRAIL的这种诱导凋亡，然后进行TIP41 siRNA转染和TRAIL处理。此外，通过用TIP41 siRNA和TRAIL处理诱导肿瘤大小减少并诱导细胞凋亡的动物实验证实。值得注意的是，MKK7 / JNK途径被证实可以介导应用TIP41 siRNA和TRAIL诱导的细胞凋亡。验证细胞凋亡是由MKK7 / JNK信号通路的激活引起的。综合起来，本发明提供了强有力的证据，包括用于TIP41表达或活性的抑制剂的药物组合物可用于癌症预防和治疗以及抗癌辅助剂。总之，包含TIP41蛋白表达或活性抑制剂的药物组合物可用于预防和治疗癌症或作为抗癌辅助剂。

7. 发明授权

US08703732B2 Composition for enhancing TRAIL sensitivity comprising inhibitors for expression or activity of TIP41 as a target gene of TRAIL sensitizer 有权
标题翻译：用于增强TRAIL灵敏度的组合物，其包含作为TRAIL增敏剂靶标基因的TIP41的表达或活性的抑制剂
公开(公告)号：US08703732B2
公开(公告)日：2014-04-22
申请号：US13579256
申请日：2011-04-01
申请人： Nam-Soon Kim , In-Sung Song , Cheol-Hee Kim , Ga Hee Ha , Hyun-Taek Kim , So-Young Jeong , Jeong-Min Kim , Joo Heon Kim , Jin-Man Kim , Soo Young Jun
发明人： Nam-Soon Kim , In-Sung Song , Cheol-Hee Kim , Ga Hee Ha , Hyun-Taek Kim , So-Young Jeong , Jeong-Min Kim , Joo Heon Kim , Jin-Man Kim , Soo Young Jun
IPC分类号： C12N15/11 , A61K48/00 , C07H21/02 , C07H21/04
CPC分类号： A61K38/16 , A61K31/7105
摘要： The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway. Taken together, the present invention provide the strong evidence that the pharmaceutical composition, including inhibitors for TIP41 expression or activity can be used for cancer prevention and treatment as well as an anti-cancer adjuvant. Taken together, the pharmaceutical composition comprising inhibitors for expression or activity of TIP41 protein may be used for prevention and treatment of cancer or as an anti-cancer adjuvant.
摘要翻译：本发明涉及包含用于预防和治疗癌症的TIP41蛋白表达或活性抑制剂的药物组合物。当显示对TRAIL的抗性的肝癌细胞系用TIP41 siRNA和TRAIL处理时，在癌细胞中诱导细胞凋亡。在具有抗TRAIL的肺癌和结肠癌的情况下也发现了相同的效果。此外，在注射Huh7肝癌细胞的肿瘤异种移植物中证实了TIP41 siRNA和TRAIL的这种诱导凋亡，然后进行TIP41 siRNA转染和TRAIL处理。此外，通过用TIP41 siRNA和TRAIL处理诱导肿瘤大小减少并诱导细胞凋亡的动物实验证实。值得注意的是，MKK7 / JNK途径被证实可以介导应用TIP41 siRNA和TRAIL诱导的细胞凋亡。验证细胞凋亡是由MKK7 / JNK信号通路的激活引起的。综合起来，本发明提供了强有力的证据，包括用于TIP41表达或活性的抑制剂的药物组合物可用于癌症预防和治疗以及抗癌辅助剂。总之，包含TIP41蛋白表达或活性抑制剂的药物组合物可用于预防和治疗癌症或作为抗癌辅助剂。

8. 发明申请

US20110251097A1 DIAGNOSTIC KIT OF COLON CANCER USING COLON CANCER RELATED MARKER AND DIAGNOSTIC METHOD THEREOF 审中-公开
标题翻译：使用结肠癌的结肠癌诊断套件相关标记及其诊断方法
公开(公告)号：US20110251097A1
公开(公告)日：2011-10-13
申请号：US13126500
申请日：2009-04-20
申请人： Eun Young Song , Hee Gu Lee , Young Il Yeom , Jae Wha Kim , Na Young Ji , Kyung-Sook Chung , Misun Won , Seon-Young Kim , Joo Heon Kim , Young Ho Kim , Ho Kyung Chun
发明人： Eun Young Song , Hee Gu Lee , Young Il Yeom , Jae Wha Kim , Na Young Ji , Kyung-Sook Chung , Misun Won , Seon-Young Kim , Joo Heon Kim , Young Ho Kim , Ho Kyung Chun
IPC分类号： C40B30/04 , G01N33/53 , G01N33/566 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The present invention relates to a composition for diagnosing colon cancer. The composition comprises at least one marker for measuring an mRNA or protein expression level of at least one gene specific for colon cancer. It can screen the genes which are overexpressed specifically only in colon cancer tissues or blood. The present invention can quantitatively analyze both the mRNA expression levels of the genes and the expression levels of the proteins encoded by the gene at the same time, thereby diagnosing colon caner of an early stage with a high level of reliability.
摘要翻译：本发明涉及用于诊断结肠癌的组合物。组合物包含至少一种用于测量至少一种对结肠癌特异性基因的mRNA或蛋白质表达水平的标记物。它可以筛选出仅在结肠癌组织或血液中过度表达的基因。本发明可以同时定量分析基因的mRNA表达水平和基因编码的蛋白质的表达水平，从而以高可靠性诊断早期的结肠癌。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式